ArticleScientific reports2025
Identification of the pathological subtypes of lung cancer brain metastases with multiparametric MRI radiomics: A feasibility study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study was aimed at differentiating brain metastases (BMs) from non-small cell lung cancer (NSCLC) vs. small cell lung cancer (SCLC), and the adenocarcinoma (AD) vs. non-adenocarcinoma (NAD) subtypes, according to radiomics features derived from multiparametric magnetic resonance imaging (MRI). A total of 276 patients with BMs, including 98 with SCLC and 178 with NSCLC, were randomly divided into training (193 cases) and test (83 cases) datasets in a 7:3 ratio. Of the 178 patients with NSCLC, 155 had primary AD, and 23 had NAD; those patients were also randomly divided into training (124 cases) and test (54 cases) datasets. Logistic regression analysis was used to construct classification models based on the radiomics features extracted from contrast-enhanced T1-weighted imaging (T1CE), T2-fluid-attenuated inversion recovery (T2-FLAIR), and diffusion-weighted imaging (DWI) images. Diagnostic efficiency was evaluated with the area under the receiver operating characteristic curve (AUC) through Delong's test, calibration curves through the Hosmer-Lemeshow test and Brier score, precision-recall curves, and decision curve analysis. Compared with radiomics features derived from a single sequence, multiparametric combined-sequence MRI radiomics features based on T1CE, T2-FLAIR, and DWI images exhibited greater specificity in distinguishing BMs originating from various lung cancer subtypes. In the training and test datasets, the AUCs of the model for the classification of SCLC and NSCLC BMs were 0.765 (95% CI 0.711, 0.822) and 0.762 (95% CI 0.671, 0.845), respectively, whereas the AUCs of the prediction models combining the three sequences in differentiating AD from NAD BMs were 0.861 (95% CI 0.756, 0.951) and 0.851 (95% CI 0.649, 0.984), respectively. The radiomics classification method based on the combination of multiple MRI sequences can be used for differentiating various lung cancer BMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.